Inclusion Criteria:  Patients aged at least 19 years Patients who have written consent for use of personal and medical information for the study purpose Patients who are prescribed and administered with approved indication for Lazerinib in Korea and not been treated with Lazertinib previously.  Exclusion Criteria:  Patients with hypersensitivity to Lazertinib or its any ingredients Patients who belong to contraindication listed on lazertinib label in Korea Patients who are treated for an indication not approved for the use of Lazertinib Women who are pregnant or may possibly become pregnant